
Elizabeth Kemmerer
Examiner (ID: 18052)
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1812, 1801, 1804, 1646, 1616, 1674 |
| Total Applications | 1850 |
| Issued Applications | 1111 |
| Pending Applications | 190 |
| Abandoned Applications | 581 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19816761
[patent_doc_number] => 20250074968
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-06
[patent_title] => ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 18/953973
[patent_app_country] => US
[patent_app_date] => 2024-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70784
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18953973
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/953973 | ACTRII PROTEINS AND USE IN TREATING POST-CAPILLARY PULMONARY HYPERTENSION | Nov 19, 2024 | Pending |
Array
(
[id] => 19949457
[patent_doc_number] => 12320817
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-03
[patent_title] => Enzyme-linked immunosorbent assay (ELISA) method and monoclonal antibody for giant panda relaxin-3 (RLN3)
[patent_app_type] => utility
[patent_app_number] => 18/808126
[patent_app_country] => US
[patent_app_date] => 2024-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 4
[patent_no_of_words] => 2865
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18808126
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/808126 | Enzyme-linked immunosorbent assay (ELISA) method and monoclonal antibody for giant panda relaxin-3 (RLN3) | Aug 18, 2024 | Issued |
Array
(
[id] => 19543171
[patent_doc_number] => 20240360207
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST
[patent_app_type] => utility
[patent_app_number] => 18/401117
[patent_app_country] => US
[patent_app_date] => 2023-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401117
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/401117 | METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST | Dec 28, 2023 | Pending |
Array
(
[id] => 19111270
[patent_doc_number] => 20240123020
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/395108
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395108
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/395108 | POLYPEPTIDES | Dec 21, 2023 | Abandoned |
Array
(
[id] => 19318339
[patent_doc_number] => 20240239882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15)
[patent_app_type] => utility
[patent_app_number] => 18/392926
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392926
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/392926 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) | Dec 20, 2023 | Pending |
Array
(
[id] => 19281587
[patent_doc_number] => 20240218061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => METHODS OF USING ACTIVIN RECEPTOR TYPE II SIGNALING INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/390085
[patent_app_country] => US
[patent_app_date] => 2023-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49132
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390085
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/390085 | METHODS OF USING ACTIVIN RECEPTOR TYPE II SIGNALING INHIBITORS | Dec 19, 2023 | Pending |
Array
(
[id] => 20413055
[patent_doc_number] => 12496317
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Compositions and methods for repairing cartilage defects
[patent_app_type] => utility
[patent_app_number] => 18/509397
[patent_app_country] => US
[patent_app_date] => 2023-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 10628
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509397
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/509397 | COMPOSITIONS AND METHODS FOR REPAIRING CARTILAGE DEFECTS | Nov 14, 2023 | Issued |
Array
(
[id] => 19232200
[patent_doc_number] => 20240189391
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
[patent_app_type] => utility
[patent_app_number] => 18/509798
[patent_app_country] => US
[patent_app_date] => 2023-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509798
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/509798 | COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | Nov 14, 2023 | Pending |
Array
(
[id] => 20413055
[patent_doc_number] => 12496317
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-16
[patent_title] => Compositions and methods for repairing cartilage defects
[patent_app_type] => utility
[patent_app_number] => 18/509397
[patent_app_country] => US
[patent_app_date] => 2023-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 10628
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509397
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/509397 | COMPOSITIONS AND METHODS FOR REPAIRING CARTILAGE DEFECTS | Nov 14, 2023 | Issued |
Array
(
[id] => 19608910
[patent_doc_number] => 12157776
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-03
[patent_title] => Anti-PAPP-A antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 18/508874
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 21812
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508874
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/508874 | Anti-PAPP-A antibodies and methods of use thereof | Nov 13, 2023 | Issued |
Array
(
[id] => 19462498
[patent_doc_number] => 20240316167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => TREATMENT OF URTICARIA
[patent_app_type] => utility
[patent_app_number] => 18/505699
[patent_app_country] => US
[patent_app_date] => 2023-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505699
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/505699 | TREATMENT OF URTICARIA | Nov 8, 2023 | Pending |
Array
(
[id] => 19448933
[patent_doc_number] => 20240309063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => TGF- B receptor II isoform, fusion peptide, methods of treatment and methods in vitro
[patent_app_type] => utility
[patent_app_number] => 18/502333
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502333
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/502333 | TGF- B receptor II isoform, fusion peptide, methods of treatment and methods in vitro | Nov 5, 2023 | Pending |
Array
(
[id] => 19556469
[patent_doc_number] => 20240368261
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION
[patent_app_type] => utility
[patent_app_number] => 18/488265
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488265
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/488265 | Compositions and methods for growth factor modulation | Oct 16, 2023 | Issued |
Array
(
[id] => 19097830
[patent_doc_number] => 20240117058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/485116
[patent_app_country] => US
[patent_app_date] => 2023-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34813
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485116
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/485116 | TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS | Oct 10, 2023 | Abandoned |
Array
(
[id] => 19097830
[patent_doc_number] => 20240117058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/485116
[patent_app_country] => US
[patent_app_date] => 2023-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34813
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485116
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/485116 | TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS | Oct 10, 2023 | Abandoned |
Array
(
[id] => 19170939
[patent_doc_number] => 20240156913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => TREATMENT AND PREVENTION OF METABOLIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/482399
[patent_app_country] => US
[patent_app_date] => 2023-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54255
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482399
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/482399 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | Oct 5, 2023 | Pending |
Array
(
[id] => 19170939
[patent_doc_number] => 20240156913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => TREATMENT AND PREVENTION OF METABOLIC DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/482399
[patent_app_country] => US
[patent_app_date] => 2023-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54255
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482399
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/482399 | TREATMENT AND PREVENTION OF METABOLIC DISEASES | Oct 5, 2023 | Pending |
Array
(
[id] => 18817507
[patent_doc_number] => 20230391847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => PROCESSES FOR MAKING AND USING A CELLULAR FIBRONECTIN COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 18/448294
[patent_app_country] => US
[patent_app_date] => 2023-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26674
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448294
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/448294 | Methods for treating an ocular condition with cellular fibronectin compositions | Aug 10, 2023 | Issued |
Array
(
[id] => 18902764
[patent_doc_number] => 20240018249
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 18/366770
[patent_app_country] => US
[patent_app_date] => 2023-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33119
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18366770
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/366770 | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient | Aug 7, 2023 | Issued |
Array
(
[id] => 18808653
[patent_doc_number] => 20230382987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER
[patent_app_type] => utility
[patent_app_number] => 18/364173
[patent_app_country] => US
[patent_app_date] => 2023-08-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -55
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18364173
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/364173 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USESTHEREOF FOR TREATING CANCER CACHEXIA AND CANCER | Aug 1, 2023 | Abandoned |